Trial ends in Request Full Access Tell Your Colleague About Jove

Methods Collections

Techniques for the detection of early stage prostate cancer

Collection Overview

This Methods Collection focuses on the early detection and diagnosis of prostate cancer (PCa). PCa is the second most frequently diagnosed cancer overall and is the fifth leading cause of cancer mortality in men. Prognosis is relatively positive if the disease is diagnosed at an early stage and a radical prostatectomy in conjunction with androgen-deprivation therapy (ADT) can be performed. Measurement of blood levels of prostate-specific antigen (PSA) and MRI are currently the most widely used early stage PCa detection methods, however, early diagnosis is still incredibly challenging. Currently, biopsy is the gold standard for early stage PCa detection, however, it is an invasive technique that can result in complications.

Recently, an increasingly large array of PCa markers have been discovered and are being assayed using novel detection methods. Specifically, plasma levels of extracellular microRNAs, circulating exosomes, as well as circulating cancer cells can be measured as prognostic biomarkers for PCa. Plasma levels are typically assayed using either a plasmon sensor chip or flow cytometry, both of which yield extremely precise marker quantitation. Additionally, MRI in conjunction with hyperpolarized [1-13C] pyruvate detects PCa and other cancers with high accuracy. This Methods Collection aims to serve as a central repository of the most significant advances in PCa early detection.


Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
simple hit counter